{"id":"TestMELD_3_0.v17","gdl_version":"2.0","concept":"gt0001","language":{"original_language":"ISO_639-1::en"},"description":{"original_author":{"name":"Umiah Gohar, Anna Axell","email":"umiah.gohar@gmail.com"},"lifecycle_state":"Not set","details":{"en":{"id":"en","keywords":[],"use":"The primary audience for this document is adult liver transplant programs preparing for implementation of MELD 3.0.  \nValues should be no more than 48 hours old.\nMELD can be used on any patient with end stage liver disease irrespective of cirrhosis etiology.\n\nMELD 3.0 improves the accuracy of the MELD calculation by: \n\n• Incorporating additional variables (albumin and sex) \n\n• Updating coefficients for existing variables \n\n• Introducing interaction terms \n\n• Lowering the maximum creatinine value from 4.0 to 3.0 mg/dL.  \n\nMELD 3.0 will apply to all adult liver transplant candidates (registered after turning 18) and to adolescent candidates (age 12-17).  ","purpose":"MELD is the standard used by the Organ Procurement and Transplantation Network (OPTN) and determines who is the highest priority to receive liver transplants in the US. Predicts estimated 90-day survival. ","misuse":"Several conditions are “standard MELD exceptions” and receive a different score:  hepatocellular carcinoma, hepatopulmonary syndrome, portopulmonary hypertension, familial amyloid polyneuropathy, primary hyperoxaluria, cystic fibrosis, hilar cholangiocarcinoma and hepatic artery thrombosis.\nOne of the exclusion criteria for the original data set was absence of acute reversible conditions such as spontaneous bacterial peritonitis or prerenal azotemia secondary to dehydration. \n"}},"other_details":{"references":"Trivedi, Hirsh D. MD1. The Evolution of the MELD Score and Its Implications in Liver Transplant Allocation: A Beginner's Guide for Trainees. ACG Case Reports Journal 9(5):p e00763, May 2022. | DOI: 10.14309/crj.0000000000000763 \n\nKim WR, Mannalithara A, Heimbach JK, Kamath PS, Asrani SK, Biggins SW, Wood NL, Gentry SE, Kwong AJ. MELD 3.0: The Model for End-Stage Liver Disease Updated for the Modern Era. Gastroenterology. 2021;161(6):1887-1895.e4. doi:10.1053/j.gastro.2021.08.050. Available from: https://www.sciencedirect.com/science/article/pii/S0016508521034697\n\nO’Leary JG, Bajaj JS. MELD 3.0: One Small Step for Womankind or One Big Step for Everyone? Gastroenterology. 2022;162(6):1780-1781. doi:10.1053/j.gastro.2021.09.014. Available from: https://www.sciencedirect.com/science/article/pii/S0016508521034934\n\nImproving Liver Allocation: MELD 3.0 FAQ [Internet]. 2023 Jul 13 [cited 2024 May 21]. Available from: https://optn.transplant.hrsa.gov/media/fyxhlkp5/improving-liver-allocation-meld-30-faq.pdf\n\nOPTN MELD serum sodium policy changes [Internet]. 2015 Nov 11 [cited 2024 May 21]. Available from: https://optn.transplant.hrsa.gov/news/meld-serum-sodium-policy-changes/"},"other_contributors":[]},"definition":{"data_bindings":{"gt0002":{"id":"gt0002","type":"INPUT","model_id":"openEHR-EHR-OBSERVATION.basic_demographic_egf.v1","template_id":"openEHR-EHR-OBSERVATION.basic_demographic_egf.v1","elements":{"gt0003":{"id":"gt0003","path":"/data[at0001]/events[at0002]/data[at0003]/items[at0004]"},"gt0067":{"id":"gt0067","path":"/data[at0001]/events[at0002]/data[at0003]/items[at0013]"}}},"gt0004":{"id":"gt0004","type":"INPUT","model_id":"openEHR-EHR-OBSERVATION.lab_test-liver_function.v1","template_id":"openEHR-EHR-OBSERVATION.lab_test-liver_function.v1","elements":{"gt0005":{"id":"gt0005","path":"/data[at0001]/events[at0002]/data[at0003]/items[at0078.4]"}}},"gt0008":{"id":"gt0008","type":"INPUT","model_id":"openEHR-EHR-OBSERVATION.laboratory_test_result-serum_albumin.v0","template_id":"openEHR-EHR-OBSERVATION.laboratory_test_result-serum_albumin.v0","elements":{"gt0009":{"id":"gt0009","path":"/data[at0001]/events[at0002]/data[at0003]/items[at0.121]"}}},"gt0010":{"id":"gt0010","type":"INPUT","model_id":"openEHR-EHR-OBSERVATION.inr.v0","template_id":"openEHR-EHR-OBSERVATION.inr.v0","elements":{"gt0011":{"id":"gt0011","path":"/data[at0001]/events[at0002]/data[at0003]/items[at0004]"}}},"gt0012":{"id":"gt0012","type":"INPUT","model_id":"openEHR-EHR-OBSERVATION.lab_test-fractional_sodium_excretion.v1","template_id":"openEHR-EHR-OBSERVATION.lab_test-fractional_sodium_excretion.v1","elements":{"gt0013":{"id":"gt0013","path":"/data[at0001]/events[at0002]/data[at0003]/items[at0078.5.1]"}}},"gt0014":{"id":"gt0014","type":"OUTPUT","model_id":"openEHR-EHR-OBSERVATION.basic_demographic_egf.v1","template_id":"openEHR-EHR-OBSERVATION.basic_demographic_egf.v1","elements":{"gt0015":{"id":"gt0015","path":"/data[at0001]/events[at0002]/data[at0003]/items[at0004]"},"gt0068":{"id":"gt0068","path":"/data[at0001]/events[at0002]/data[at0003]/items[at0013]"}}},"gt0016":{"id":"gt0016","type":"OUTPUT","model_id":"openEHR-EHR-OBSERVATION.lab_test-liver_function.v1","template_id":"openEHR-EHR-OBSERVATION.lab_test-liver_function.v1","elements":{"gt0017":{"id":"gt0017","path":"/data[at0001]/events[at0002]/data[at0003]/items[at0078.4]"}}},"gt0018":{"id":"gt0018","type":"INPUT","model_id":"openEHR-EHR-OBSERVATION.lab_test_creatinine.v1","template_id":"openEHR-EHR-OBSERVATION.lab_test_creatinine.v1","elements":{"gt0019":{"id":"gt0019","path":"/data[at0001]/events[at0002]/data[at0003]/items[at0005]"}}},"gt0020":{"id":"gt0020","type":"OUTPUT","model_id":"openEHR-EHR-OBSERVATION.lab_test_creatinine.v1","template_id":"openEHR-EHR-OBSERVATION.lab_test_creatinine.v1","elements":{"gt0021":{"id":"gt0021","path":"/data[at0001]/events[at0002]/data[at0003]/items[at0005]"}}},"gt0022":{"id":"gt0022","type":"OUTPUT","model_id":"openEHR-EHR-OBSERVATION.laboratory_test_result-serum_albumin.v0","template_id":"openEHR-EHR-OBSERVATION.laboratory_test_result-serum_albumin.v0","elements":{"gt0023":{"id":"gt0023","path":"/data[at0001]/events[at0002]/data[at0003]/items[at0.121]"}}},"gt0026":{"id":"gt0026","type":"OUTPUT","model_id":"openEHR-EHR-OBSERVATION.lab_test-fractional_sodium_excretion.v1","template_id":"openEHR-EHR-OBSERVATION.lab_test-fractional_sodium_excretion.v1","elements":{"gt0027":{"id":"gt0027","path":"/data[at0001]/events[at0002]/data[at0003]/items[at0078.5.1]"}}},"gt0054":{"id":"gt0054","type":"OUTPUT","model_id":"openEHR-EHR-OBSERVATION.meld_score.v1","template_id":"openEHR-EHR-OBSERVATION.meld_score.v1","elements":{"gt0055":{"id":"gt0055","path":"/data[at0001]/events[at0002]/data[at0003]/items[at0005]"}}},"gt0058":{"id":"gt0058","type":"OUTPUT","model_id":"openEHR-EHR-EVALUATION.meld_score.v1","template_id":"openEHR-EHR-EVALUATION.meld_score.v1","elements":{"gt0059":{"id":"gt0059","path":"/data[at0001]/items[at0002]"}}}},"rules":{"gt0049":{"id":"gt0049","priority":21,"then":["$gt0050|Boolean_gender| = 1"],"when":["$gt0003|Gender| == local::at0006|Female|"],"description":""},"gt0051":{"id":"gt0051","priority":20,"then":["$gt0050|Boolean_gender| = 0"],"when":["$gt0003|Gender| == local::at0005|Male|"],"description":""},"gt0069":{"id":"gt0069","priority":19,"then":["$gt0050|Boolean_gender| = 1"],"when":["$gt0067|Age| < 18,a && $gt0067|Age| >= 12,a"],"description":"In the current liver allocation system, adolescent candidates (age at least 12 and less than 18) are assigned a MELD score. Under this new policy, adolescent candidates will continue to utilize MELD 3.0, but both male and female adolescent candidates will receive the 1.33 points that will be provided to all adult female candidates. This is based on data that shows there is no sexbased disparity in the adolescent population. Both male and female adolescent candidates registered before turning 18 will maintain the 1.33 points if they remain on the OPTN Waiting List after turning 18.  "},"gt0044":{"id":"gt0044","priority":18,"then":["$gt0045|Albumin conversion factor| = 10.0"],"when":["$gt0009|Serum Albumin|.unit == 'gm/dl'"]},"gt0046":{"id":"gt0046","priority":16,"then":["$gt0023|Serum Albumin| = $gt0009|Serum Albumin|","$gt0009|Serum Albumin|.unit = 'gm/dl'"],"when":["( $gt0009|Serum Albumin|.magnitude >= 1.5 ) || $gt0009|Serum Albumin|.magnitude <= 3.5 )"]},"gt0048":{"id":"gt0048","priority":15,"then":["$gt0023|Serum Albumin| = 3.5,gm/dl"],"when":["$gt0023|Serum Albumin| > 3.5,gm/dl"],"description":""},"gt0047":{"id":"gt0047","priority":14,"then":["$gt0023|Serum Albumin| = 1.5,gm/dl"],"when":["$gt0023|Serum Albumin| < 1.5,gm/dl"],"description":""},"gt0042":{"id":"gt0042","priority":13,"then":["$gt0011|INR|.magnitude = 1,1","$gt0011|INR|.unit = 1"],"when":["$gt0011|INR|.magnitude < 1,1"]},"gt0039":{"id":"gt0039","priority":12,"then":["$gt0027|serum Sodium (sNa)| = $gt0013|serum Sodium (sNa)|","$gt0013|serum Sodium (sNa)|.unit = 'mmol/l'"],"when":["( $gt0013|serum Sodium (sNa)|.magnitude >= 125 ) || ( $gt0013|serum Sodium (sNa)|.magnitude <= 137 )"]},"gt0041":{"id":"gt0041","priority":11,"then":["$gt0027|serum Sodium (sNa)|.magnitude = 137","$gt0027|serum Sodium (sNa)|.unit = 'mmol/l'"],"when":["( $gt0013|serum Sodium (sNa)| > 137,mmol/l ) || ( $gt0013|serum Sodium (sNa)| > 137,mEq/l )"],"description":""},"gt0040":{"id":"gt0040","priority":10,"then":["$gt0027|serum Sodium (sNa)|.magnitude = 125","$gt0027|serum Sodium (sNa)|.unit = 'mmol/l'"],"when":["( $gt0013|serum Sodium (sNa)| < 125,mmol/l ) || ( $gt0013|serum Sodium (sNa)| < 125,mEq/l )"]},"gt0032":{"id":"gt0032","priority":9,"then":["$gt0033|Creatinine conversion factor| = 88.42"],"when":["$gt0019|Serum Creatinine|.unit == 'mg/dl'"]},"gt0034":{"id":"gt0034","priority":8,"then":["$gt0021|Serum Creatinine|.magnitude = $gt0019|Serum Creatinine|.magnitude / $gt0033|Creatinine conversion factor|","$gt0021|Serum Creatinine|.precision = 2","$gt0021|Serum Creatinine|.unit = 'µmol/l'"],"when":["$gt0019|Serum Creatinine| != null"]},"gt0036":{"id":"gt0036","priority":7,"then":["$gt0021|Serum Creatinine| = 3,mg/dl"],"when":["$gt0021|Serum Creatinine| > 3,mg/dl"],"description":""},"gt0035":{"id":"gt0035","priority":6,"then":["$gt0021|Serum Creatinine| = 1,mg/dl"],"when":["$gt0021|Serum Creatinine| < 1,mg/dl"],"description":""},"gt0028":{"id":"gt0028","priority":5,"then":["$gt0029|Bilirubin conversion factor| = 17.1"],"when":["$gt0005|Total bilirubin|.unit == 'mg/dl'"]},"gt0030":{"id":"gt0030","priority":4,"then":["$gt0017|Total bilirubin|.magnitude = $gt0005|Total bilirubin|.magnitude / $gt0029|Bilirubin conversion factor|","$gt0017|Total bilirubin|.precision = 2","$gt0017|Total bilirubin|.unit = 'µmol/l'"],"when":["$gt0005|Total bilirubin| != null"]},"gt0031":{"id":"gt0031","priority":3,"then":["$gt0017|Total bilirubin| = 1,mg/dl"],"when":["$gt0017|Total bilirubin| < 1,mg/dl"],"description":""},"gt0052":{"id":"gt0052","priority":2,"then":["$gt0055|MELD score 3.0|.magnitude = 1.33 * ( $gt0050|Boolean_gender| ) + ( 4.56 * log ( $gt0017|Total bilirubin|.magnitude ) ) + ( 0.82 * ( 137 - $gt0027|serum Sodium (sNa)|.magnitude ) ) - ( 0.24 * ( 137 - $gt0027|serum Sodium (sNa)|.magnitude ) * log ( $gt0017|Total bilirubin|.magnitude ) ) + ( 9.09 * log ( $gt0011|INR|.magnitude ) ) + ( 11.14 * log ( $gt0021|Serum Creatinine|.magnitude ) ) + ( 1.85 * ( 3.5 - $gt0023|Serum Albumin|.magnitude ) ) - ( 1.83 * ( 3.5 - $gt0023|Serum Albumin|.magnitude ) * log ( $gt0021|Serum Creatinine|.magnitude ) ) + 6"],"when":["$gt0017|Total bilirubin| != null","$gt0023|Serum Albumin| != null","$gt0011|INR| != null","$gt0027|serum Sodium (sNa)| != null","$gt0021|Serum Creatinine| != null"]},"gt0066":{"id":"gt0066","priority":1,"then":["$gt0059|Estimated 90-day survival| = ( 0.946 ^ exp ( 0.17698 * $gt0055|MELD score 3.0|.magnitude - 3.56 ) ) * 100"],"when":["$gt0055|MELD score 3.0|.magnitude != null"]},"gt0070":{"id":"gt0070","priority":17,"then":["$gt0023|Serum Albumin|.magnitude = $gt0009|Serum Albumin|.magnitude / $gt0045|Albumin conversion factor|","$gt0023|Serum Albumin|.precision = 2","$gt0023|Serum Albumin|.unit = 'gm/l'"],"when":["$gt0009|Serum Albumin| != null"]}},"default_actions":["$gt0045|Albumin conversion factor| = 1","$gt0033|Creatinine conversion factor| = 1","$gt0029|Bilirubin conversion factor| = 1","$gt0038|Sodium conversion factor| = 1","$gt0050|Boolean_gender| = 1"],"pre_conditions":["$gt0067|Age|.magnitude >= 12"]},"ontology":{"term_definitions":{"en":{"id":"en","terms":{"gt0001":{"id":"gt0001","text":"Test MELD 3.0","description":"MELD 3.0, implemented 2023, is the current standard calculation for organ transplantation consideration in the United States.\n\nMELD 3.0 will address the sex-based disparity that has existed in liver allocation since the original MELD score was implemented. MELD 3.0 includes 1.33 points for candidates who are female. In addition, MELD 3.0 better predicts risk of waitlist mortality for all liver candidates by updating the coefficients for each of the variables in the score, adding albumin as a factor, introducing interaction terms, and lowering the maximum creatinine value from 4.0 to 3.0 mg/dL.  \n\nFor all MELD candidates (age 12 and older), transplant programs will be required to submit an albumin value when editing a candidate record, as albumin is now included in the MELD 3.0 calculation. Albumin is already required when adding an adult or adolescent liver candidate to the OPTN Waiting List. "},"gt0003":{"text":"Gender","description":"i","id":"gt0003"},"gt0005":{"text":"Total bilirubin","description":"i","id":"gt0005"},"gt0009":{"text":"Serum Albumin","description":"i","id":"gt0009"},"gt0011":{"text":"INR","description":"i","id":"gt0011"},"gt0013":{"text":"serum Sodium (sNa)","description":"i","id":"gt0013"},"gt0015":{"text":"Gender","id":"gt0015"},"gt0017":{"id":"gt0017","text":"Total bilirubin"},"gt0019":{"text":"Serum Creatinine","description":"i","id":"gt0019"},"gt0021":{"id":"gt0021","text":"Serum Creatinine"},"gt0023":{"id":"gt0023","text":"Serum Albumin"},"gt0027":{"id":"gt0027","text":"serum Sodium (sNa)"},"gt0028":{"id":"gt0028","text":"Bilirubin conversion rule","description":""},"gt0029":{"text":"Bilirubin conversion factor","id":"gt0029"},"gt0030":{"id":"gt0030","text":"Bilirubin µmol/L to mg/dL","description":""},"gt0031":{"id":"gt0031","text":"Bilirubin <1  mg/dL","description":""},"gt0032":{"id":"gt0032","text":"Creatinine conversion rule","description":""},"gt0033":{"text":"Creatinine conversion factor","id":"gt0033"},"gt0034":{"id":"gt0034","text":"Creatinine µmol to mg/dL","description":""},"gt0035":{"id":"gt0035","text":"Creatinine <1 mg/dL","description":""},"gt0036":{"id":"gt0036","text":"Creatinine >3 mg/dL","description":""},"gt0038":{"text":"Sodium conversion factor","id":"gt0038"},"gt0039":{"id":"gt0039","text":"Sodium normal range","description":"No need for conversion mmol/L -> mEq/L, conversion factor = 1."},"gt0040":{"id":"gt0040","text":"Sodium <125 ","description":""},"gt0041":{"id":"gt0041","text":"Sodium >137","description":""},"gt0042":{"id":"gt0042","text":"INR <1","description":""},"gt0044":{"id":"gt0044","text":"Albumin conversion rule","description":""},"gt0045":{"text":"Albumin conversion factor","id":"gt0045"},"gt0046":{"id":"gt0046","text":"Albumin normal range","description":""},"gt0047":{"id":"gt0047","text":"Albumin <1.5","description":""},"gt0048":{"id":"gt0048","text":"Albumin >3.5","description":""},"gt0049":{"id":"gt0049","text":"Gender Female","description":""},"gt0050":{"text":"Boolean_gender","id":"gt0050"},"gt0051":{"id":"gt0051","text":"Gender Male","description":""},"gt0052":{"id":"gt0052","text":"MELD 3.0 score","description":"Predicts three-month survival in patients (age 12+) with liver cirrhosis,  with higher scores correlating with increased severity of liver dysfunction."},"gt0055":{"id":"gt0055","text":"MELD score 3.0"},"gt0059":{"id":"gt0059","text":"Estimated 90-day survival"},"gt0066":{"id":"gt0066","text":"90-day survival score","description":"Estimated 90-day survival = 0.946exp(0.17698*MELD 3.0 – 3.56) * 100"},"gt0067":{"text":"Age","description":"i","id":"gt0067"},"gt0068":{"id":"gt0068","text":"Age"},"gt0069":{"id":"gt0069","text":"Adolescent = Female","description":"In the current liver allocation system, adolescent candidates (age at least 12 and less than 18) are assigned a MELD score. Under this new policy, adolescent candidates will continue to utilize MELD 3.0, but both male and female adolescent candidates will receive the 1.33 points that will be provided to all adult female candidates. This is based on data that shows there is no sexbased disparity in the adolescent population. Both male and female adolescent candidates registered before turning 18 will maintain the 1.33 points if they remain on the OPTN Waiting List after turning 18.  "},"gt0070":{"id":"gt0070","text":"Albumin g/L to g/dL","description":""}}}},"term_bindings":{"LOINC":{"id":"LOINC","bindings":{"gt0011":{"termId":"gt0011","termText":"INR","codes":["LOINC::6301-6"],"terminology":"LOINC"},"gt0025":{"termId":"gt0025","termText":"INR","codes":["LOINC::6301-6"],"terminology":"LOINC"},"gt0005":{"termId":"gt0005","termText":"Total bilirubin","codes":["LOINC::42719-5"],"terminology":"LOINC"},"gt0017":{"termId":"gt0017","termText":"Total bilirubin","codes":["LOINC::42719-5"],"terminology":"LOINC"},"gt0023":{"termId":"gt0023","termText":"Serum Albumin","codes":["LOINC::1751-7"],"terminology":"LOINC"},"gt0013":{"termId":"gt0013","termText":"serum Sodium (sNa)","codes":["LOINC::2947-0"],"terminology":"LOINC"},"gt0027":{"termId":"gt0027","termText":"serum Sodium (sNa)","codes":["LOINC::2947-0"],"terminology":"LOINC"},"gt0009":{"termId":"gt0009","termText":"Serum Albumin","codes":["LOINC::\t1751-7"],"terminology":"LOINC"},"gt0019":{"termId":"gt0019","termText":"Serum Creatinine","codes":["LOINC::38483-4"],"terminology":"LOINC"},"gt0021":{"termId":"gt0021","termText":"Serum Creatinine","codes":["LOINC::38483-4"],"terminology":"LOINC"}}}}}}